Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) – Analysts at Leerink Partnrs upped their Q2 2024 earnings estimates for Compass Therapeutics in a research report issued on Monday, May 13th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.11) per share for the quarter, up from their prior estimate […]

Related Keywords

United States , Leerink Partnrs , Nasdaq , Cm Management , Element Capital Management , Blackstone Inc , Compass Therapeutics Company Profile , Compass Therapeutics Inc , Compass Therapeutics , Free Report , Compass Therapeutic , Get Free Report , Capital Management , Pale Fire Capital , Fire Capital , Compass Therapeutics Daily ,